AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 211 min read

Helus Pharma Inc. Stock 12‑Month Price Target Raised to $43.62, Implies 299% Upside

Helus Pharma Inc.'s average stock price target increased from $40.77 to $43.62, according to 9 analysts, with a potential 299% upside from the Oct. 20 closing price. The consensus rating remains 'Buy' among 10 analysts.

Original reporting
tradingview.com
Published Oct 21, 2026, 4:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 4:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Helus Pharma Inc. Stock 12‑Month Price Target Raised to $43.62, Implies 299% Upside — source image
Source · tradingview.com
Decision brief

The 30-second read

Low
01

Why it matters

The target raise signals improved expectations but lacks a concrete catalyst.

02

Market read

Modest relevance; may affect short‑term sentiment for the stock and similar small‑cap biotech names.

03

What to watch

Potential dilution from upcoming financing or clinical trial risk.

Relevance 5/10Novelty 5/10Timing: today

Background

Helus Pharma is a micro‑cap biotech with recent analyst coverage.

Market effects

Sector

May lift sentiment for small-cap biotech peers.

Regional

Limited to US biotech market.

Global

Minimal.

Counterpoint

What could challenge this read

Target could be overly optimistic; price may remain flat.

Key entities

  • company
    Helus Pharma Inc.

    US‑listed biotech (NASDAQ:HLPH).

Read at source← All news

Related articles

SEP 18
$HELPMed

HELP Stock Gaps Higher, Then Fades, On $35 Barclays Target Ahead Of Q4 Psychedelic Drug Trial Results

Helus Pharma (HELP) shares rose to a 52-week high of $15.15 before falling 11% after Barclays initiated coverage with an Overweight rating and $35 price target. The company awaits Q4 trial results for its psychedelic drug HLP003, with FDA Breakthrough Therapy status. Analysts' average price target is $41.40, implying 195% upside. HELP has gained 53% year-to-date.

stocktwits.com2 min
AUG 14
$HELPMed

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

Helus Pharma (Nasdaq: HELP) reported fiscal Q1 2027 results for the quarter ended June 30, 2026. Cash was $166.4M. Net loss was $47.8M vs $24.6M a year earlier. The company said Phase 3 APPROACH enrollment for HLP003 in MDD is complete with topline data expected in Q4 2026, and a DDI study showed no meaningful PK interaction. It also completed a $50M underwritten offering in June 2026.

finanznachrichten.de6 min
JUL 21
$HELPMed

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Helus Pharma (Nasdaq: HELP) said it completed enrollment in its Phase 3 APPROACH study of HLP003, an investigational adjunctive treatment for major depressive disorder, ahead of schedule. The company reported 223 enrolled participants and expects topline data in Q4 2026. Phase 2 results cited include ~23-point MADRS reduction and 100% response/71% remission.

prnewswire.com2 min
JUL 17
$LLYMedAI 8/10

Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time

Eli Lilly (NYSE: LLY) agreed to acquire AtaiBeckley Inc. (NASDAQ: ATAI) for $6.75 per share in cash (about $2.8B) plus up to $2.50 per share in milestone-linked contingent value rights, totaling up to about $3.8B. The deal was approved by both boards and is expected to close in Q3. The article cites Helus Pharma (NASDAQ: HELP) Phase 3 readout in Q4 2026.

prnewswire.com7 min